The potential benefits of a new class of medications, sodium-dependent glucose cotransporter-2 therapy (or SGLT-2s), for type 2 diabetes is promising, but where will they fit in the treatment of diabetes and what are the risks? Join host Dr. Steven Edelman and his guest, professor of medicine at the Veterans Affairs Medical Center in San Diego, California, Dr. Robert Henry, as they discuss the mechanism, benefits and potential cardiovascular risks of this new class of medication.
ReachMD
Be part of the knowledge.™Where Do SGLT-2s Fit in the Treatment of Diabetes?
Choose a format
Media formats available:
Facebook Comments